UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 25, 2023

UNIVERSAL HEALTH SERVICES, INC.

(Exact name of registrant as specified in its charter)

DELAWARE (State or other jurisdiction of

Incorporation or Organization)

1-10765 (Commission File Number) 23-2077891 (I.R.S. Employer Identification No.)

UNIVERSAL CORPORATE CENTER 367 SOUTH GULPH ROAD KING OF PRUSSIA, PENNSYLVANIA 19406

(Address of principal executive office) (Zip Code)

Registrant's telephone number, including area code (610) 768-3300

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Dere-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered				
Class B Common Stock	UHS	New York Stock Exchange				

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company \Box

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition

On October 25, 2023, Universal Health Services, Inc. issued the press release attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

99.1	Universal Health Services, Inc., press release, dated October 25, 2023.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

Exhibit Index

Exhibit No.	Exhibit
99.1	Universal Health Services, Inc., press release, dated October 25, 2023.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Universal Health Services, Inc.

By: /s/ Steve Filton

Name: Steve Filton Title: Executive Vice President and Chief Financial Officer

Date: October 26, 2023

CONTACT: Steve Filton Chief Financial Officer 610-768-3300

<u>UNIVERSAL HEALTH SERVICES, INC.</u> <u>ANNOUNCES 2023 THIRD QUARTER FINANCIAL RESULTS</u>

Consolidated Results of Operations, As Reported and As Adjusted – Three-month periods ended September 30, 2023 and 2022:

KING OF PRUSSIA, PA – Universal Health Services, Inc. (NYSE: UHS) announced today that its reported net income attributable to UHS was \$167.0 million, or \$2.40 per diluted share, during the third quarter of 2023, as compared to \$182.8 million, or \$2.50 per diluted share, during the third quarter of 2022. Net revenues increased by 6.8% to \$3.563 billion during the third quarter of 2023, as compared to \$3.336 billion during the third quarter of 2022.

As reflected on the Schedule of Non-GAAP Supplemental Information ("Supplemental Schedule"), our adjusted net income attributable to UHS during the third quarter of 2023 was \$177.5 million, or \$2.55 per diluted share, as compared to \$185.8 million, or \$2.54 per diluted share, during the third quarter of 2022. As reflected on the Supplemental Schedule, included in our reported results were unrealized after-tax losses of \$10.5 million, or \$.15 per diluted share (\$13.8 million pre-tax), during the third quarter of 2023, and \$3.0 million, or \$.04 per diluted share (\$3.9 million pre-tax) during the third quarter of 2022. These unrealized losses, which are included in "Other (income) expense, net", resulted from decreases in the market value of certain equity securities.

As calculated on the attached Supplemental Schedule, our earnings before interest, taxes, depreciation & amortization ("EBITDA net of NCI", NCI is net income attributable to noncontrolling interests), was \$410.1 million during the third quarter of 2023, as compared to \$421.7 million during the third quarter of 2022. Our adjusted earnings before interest, taxes, depreciation & amortization ("Adjusted EBITDA net of NCI"), which excludes the impact of other (income) expense, net, was \$421.5 million during the third quarter of 2023, as compared to \$427.8 million during the third quarter of 2022.

Consolidated Results of Operations, As Reported and As Adjusted – Nine-month periods ended September 30, 2023 and 2022:

Reported net income attributable to UHS was \$501.4 million, or \$7.09 per diluted share, during the first nine months of 2023, as compared to \$500.8 million, or \$6.71 per diluted share, during the first nine months 2022. Net revenues increased by 6.3% to \$10.578 billion during the first nine months of 2023, as compared to \$9.952 billion during the comparable period of 2022.

As reflected on the Supplemental Schedule, our adjusted net income attributable to UHS during the first nine months of 2023, was \$524.5 million, or \$7.42 per diluted share, as compared to \$513.1 million, or \$6.88 per diluted share, during the nine-month period ended September 30, 2022.

As reflected on the Supplemental Schedule, included in our reported results were unrealized after-tax losses of \$23.0 million, or \$.33 per diluted share, (\$30.1 million pre-tax) during the first nine months of 2023 and \$12.4 million, or \$.17 per diluted share, (\$16.1 million pre-tax) during the first nine months of 2022. These unrealized losses, which are included in "Other (income) expense, net", resulted from decreases in the market value of certain equity securities.

As calculated on the attached Supplemental Schedule, our earnings before interest, taxes, depreciation & amortization ("EBITDA net of NCI"), was \$1.237 billion during the first nine months of 2023, as compared to \$1.175 billion during the first nine months of 2022. Our adjusted earnings before interest, taxes, depreciation & amortization ("Adjusted EBITDA net of NCI"), which excludes the impact of other (income) expense, net, was

\$1.268 billion during the first nine months of 2023, as compared to \$1.190 billion during the comparable period of 2022.

Acute Care Services - Three and nine-month periods ended September 30, 2023 and 2022:

During the third quarter of 2023, at our acute care hospitals owned during both periods ("same facility basis"), adjusted admissions (adjusted for outpatient activity) increased by 6.8% while adjusted patient days increased by 3.8%, as compared to the third quarter of 2022. At these facilities, during the third quarter of 2023, net revenue per adjusted admission increased by 0.4% while net revenue per adjusted patient day increased by 3.3%, as compared to the third quarter of 2022. Net revenues generated from our acute care services, on a same facility basis, increased by 7.5% during the third quarter of 2023, as compared to the third quarter of 2022.

During the nine-month period ended September 30, 2023, at our acute care hospitals on a same facility basis, adjusted admissions increased by 8.3% while adjusted patient days increased by 4.8%, as compared to the first nine months of 2022. At these facilities, during the first nine months of 2023, net revenue per adjusted admission decreased by 2.0% while net revenue per adjusted patient day increased by 1.3%, as compared to the first nine months of 2022. Net revenues generated from our acute care services, on a same facility basis, increased by 6.9% during the first nine months of 2023, as compared to the comparable period of 2022.

Behavioral Health Care Services – Three and nine-month periods ended September 30, 2023 and 2022:

During the third quarter of 2023, at our behavioral health care facilities on a same facility basis, adjusted admissions increased by 0.8% while adjusted patient days increased by 1.1%, as compared to the third quarter of 2022. At these facilities, during the third quarter of 2023, net revenue per adjusted admission increased by 6.8% and net revenue per adjusted patient day increased by 6.5%, as compared to the third quarter of 2022. Net revenues generated from our behavioral health care services, on a same facility basis, increased by 7.6% during the third quarter of 2023, as compared to the third quarter of 2022.

During the nine-month period ended September 30, 2023, at our behavioral health care facilities on a same facility basis, adjusted admissions increased by 3.8% while adjusted patient days increased by 2.4%, as compared to the first nine months of 2022. At these facilities, during the first nine months of 2023, net revenue per adjusted admission increased by 4.4% and net revenue per adjusted patient day increased by 5.9%, as compared to the first nine months of 2022. Net revenues generated from our behavioral health care services, on a same facility basis, increased by 8.3% during the first nine months of 2023, as compared to the comparable period of 2022.

Net Cash Provided by Operating Activities and Liquidity:

Net Cash Provided by Operating Activities:

During the nine-month period ended September 30, 2023, our net cash provided by operating activities was \$815 million as compared to \$699 million during the first nine months of 2022. Included in the \$117 million net increase in our net cash provided by operating activities was a favorable change of \$109 million in other working capital accounts due primarily to the timing of disbursements for accrued compensation and accounts payable. *Liquidity:*

As of September 30, 2023, we had \$721 million of aggregate available borrowing capacity pursuant to our \$1.2 billion revolving credit facility, net of outstanding borrowings and letters of credit.

Stock Repurchase Program:

As of December 31, 2022, we had an aggregate remaining repurchase authorization of approximately \$947 million pursuant to our stock repurchase program. Pursuant to the terms of our stock repurchase program, shares of our Class B Common Stock may be repurchased, from time to time as conditions allow, on the open market or in negotiated private transactions.

During the third quarter of 2023, we have repurchased 1.32 million shares at an aggregate cost of approximately \$175.1 million (approximately \$133 per share) pursuant to the program. During the first nine months of 2023, we have repurchased approximately 2.73 million shares at an aggregate cost of approximately \$367.2 million (approximately \$135 per share) pursuant to the program.

As of September 30, 2023, we had an aggregate available repurchase authorization of approximately \$580 million.

Conference call information:

We will hold a conference call for investors and analysts at 9:00 a.m. eastern time on October 26, 2023. A live webcast of the call will be available on our website at www.uhs.com. To participate via telephone, please register in advance at this link.

Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the call will be available for one full year following the live call.

General Information, Forward-Looking Statements and Risk Factors and Non-GAAP Financial Measures:

One of the nation's largest and most respected providers of hospital and healthcare services, Universal Health Services, Inc. has built an impressive record of achievement and performance. Growing steadily since our inception into an esteemed Fortune 500 corporation, our annual revenues during 2022 were approximately \$13.4 billion. UHS ranked #311 on the Fortune 500; and #434 on *Forbes*' list of America's Largest Public Companies. UHS was again recognized as one of the World's Most Admired Companies by *Fortune*.

Our operating philosophy is as effective today as it was upon the Company's founding in 1979, enabling us to provide compassionate care to our patients and their loved ones. Our strategy includes building or acquiring high quality hospitals in rapidly growing markets, investing in the people and equipment needed to allow each facility to thrive, and becoming the leading healthcare provider in each community we serve.

Headquartered in King of Prussia, PA, UHS has approximately 93,800 employees and, through its subsidiaries, operates 27 inpatient acute care hospitals, 331 inpatient behavioral health facilities, 43 outpatient facilities and ambulatory care access points, an insurance offering, a physician network and various related services located in 39 states, Washington, D.C., the United Kingdom and Puerto Rico. It acts as the advisor to Universal Health Realty Income Trust, a real estate investment trust (NYSE:UHT). For additional information visit www.uhs.com.

This press release contains forward-looking statements based on current management expectations. Numerous factors, including those disclosed herein, those related to the potential impact of COVID-19 on our operations and financial results, those related to healthcare industry trends and those detailed in our filings with the Securities and Exchange Commission (as set forth in *Item 2-Forward Looking Statements and Risk Factors* in our Form 10-Q for the quarter ended June 30, 2023 and in *Item 1A-Risk Factors*, and *Item 7-Forward-Looking Statements and Risk Factors*, in our Form 10-K for the year ended December 31, 2022), may cause the results to differ materially from those anticipated in the forward-looking statements. These statements are subject to risks and uncertainties and therefore actual results may differ materially. Readers should not place undue reliance on such forward-looking statements which reflect management's view only as of the date hereof. We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Many of the factors that could affect our future results are beyond our control or ability to predict, including, but not limited to:

- The nationwide shortage of nurses and other clinical staff and support personnel has been a significant operating issue facing us and other healthcare providers. In some areas, the labor scarcity is putting a strain on our resources and staff, which has required us to utilize higher-cost temporary labor and pay premiums above standard compensation for essential workers. These factors, which had a material unfavorable impact on our results of operations during 2022, could continue to have an unfavorable material impact on our results of operations for the foreseeable future.
- The impact of the COVID-19 pandemic, which began in March, 2020, has had a material effect on our operations and financial results, at various times, since that time. We cannot predict if there will be future disruptions caused by the COVID-19 pandemic.

- A significant portion of our revenues are derived from federal and state government programs including the Medicare and Medicaid programs. Payments from these programs are subject to statutory and regulatory changes, administrative rulings, interpretations and determinations, requirements for utilization review, and federal and state funding restrictions. Changes to these programs, if adopted, could materially affect program payments which could materially impact our results of operations.
- The increase in interest rates has substantially increased our borrowings costs and reduced our ability to access the capital markets on favorable terms. Additional increases in interest rates could have a significant unfavorable impact on our future results of operations and the resulting effect on the capital markets could adversely affect our ability to carry out our strategy.

We believe that adjusted net income attributable to UHS, adjusted net income attributable to UHS per diluted share, EBITDA net of NCI and Adjusted EBITDA net of NCI, which are non-GAAP financial measures ("GAAP" is Generally Accepted Accounting Principles in the United States of America), are helpful to our investors as measures of our operating performance. In addition, we believe that, when applicable, comparing and discussing our financial results based on these measures, as calculated, is helpful to our investors since it neutralizes the effect of material items impacting our net income attributable to UHS, such as, changes in the market value of shares of certain equity securities and other potential material items that are nonrecurring or non-operational in nature including, but not limited to, impairments of goodwill, long-lived and intangible assets, reserves for various matters including settlements, legal judgments and lawsuits, costs related to extinguishment of debt, gains/losses on sales of assets and businesses, potential impacts of non-ordinary acquisitions, divestitures, joint ventures or other strategic transactions, and other amounts that may be reflected in the current or prior year financial statements that relate to prior periods. To obtain a complete understanding of our financial performance these measures should be examined in connection with net income attributable to UHS, as determined in accordance with GAAP, and as presented in the condensed consolidated financial statements and notes thereto in this report or in our other filings with the Securities and Exchange Commission including our Report on Form 10-Q for the quarter ended June 30, 2023 and our Report on Form 10-K for the year ended December 31, 2022. Since the items included or excluded from these measures are significant components in understanding and assessing financial performance under GAAP, these measures should not be considered to be alternatives to net income as a measure of our operating performance or profitability. Since these measures, as presented, are not determined in accordance with GAAP and are thus susceptible to varying calculations, they may not be comparable to other similarly titled measures of other companies. Investors are encouraged to use GAAP measures when evaluating our financial performance.

(more)

Consolidated Statements of Income (in thousands, except per share amounts) (unaudited)

	Three months ended September 30,			Nine months ended September 30,				
	 2023		2022		2023		2022	
Net revenues	\$ 3,562,774		3,336,027	\$	10,578,430		9,952,390	
Operating charges:								
Salaries, wages and benefits	1,784,870		1,677,431		5,308,476		5,061,173	
Other operating expenses	941,219		837,241		2,758,484		2,526,060	
Supplies expense	378,667		366,337		1,138,950		1,092,403	
Depreciation and amortization	137,195		145,874		422,560		433,508	
Lease and rental expense	35,466		33,264		105,775		97,075	
	 3,277,417		3,060,147		9,734,245		9,210,219	
Income from operations	285,357		275,880		844,185		742,171	
Interest expense, net	53,378		35,653		153,085		83,002	
Other (income) expense, net	 11,472		6,015		31,797		15,244	
Income before income taxes	220,507		234,212		659,303		643,925	
Provision for income taxes	 52,499		57,401		159,618		157,312	
Net income	168,008		176,811		499,685		486,613	
Less: Net income (loss) attributable to noncontrolling interests ("NCI")	1,019		(6,003)		(1,732)		(14,176)	
Net income attributable to UHS	\$ 166,989	\$	182,814	\$	501,417	\$	500,789	
Basic earnings per share attributable to UHS (a)	\$ 2.42	\$	2.52	\$	7.18	\$	6.78	
Diluted earnings per share attributable to UHS (a)	\$ 2.40	\$	2.50	\$	7.09	\$	6.71	

Footnotes to Consolidated Statements of Income

(in thousands, except per share amounts)

(unaudited)

	Three r ended Sept	 -	Nine months ended September				
	 2023	 2022		2023		2022	
(a) Earnings per share calculation:	 	 					
Basic and diluted:							
Net income attributable to UHS	\$ 166,989	\$ 182,814	\$	501,417	\$	500,789	
Less: Net income attributable to unvested restricted share grants	 (52)	 (179)		(242)		(592)	
Net income attributable to UHS - basic and diluted	\$ 166,937	\$ 182,635	\$	501,175	\$	500,197	
Weighted average number of common shares - basic	 68,867	 72,595		69,825		73,769	
Basic earnings per share attributable to UHS:	\$ 2.42	\$ 2.52	\$	7.18	\$	6.78	
Weighted average number of common shares	68,867	72,595		69,825		73,769	
Add: Other share equivalents	757	465		825		743	
Weighted average number of common shares and equiv diluted	 69,624	 73,060		70,650		74,512	
Diluted earnings per share attributable to UHS:	\$ 2.40	\$ 2.50	\$	7.09	\$	6.71	

Schedule of Non-GAAP Supplemental Information ("Supplemental Schedule").

For the Three Months ended September 30, 2023 and 2022

(in thousands, except per share amounts)

(unaudited)

Calculation of Earnings/Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA/Adjusted EBITDA net of NCI")

	Three	months ended	% Net	Three	months ended	% Net
	<u>Septe</u>	<u>mber 30, 2023</u>	revenues	<u>Septe</u>	<u>mber 30, 2022</u>	revenues
Net income attributable to UHS	\$	166,989		\$	182,814	
Depreciation and amortization		137,195			145,874	
Interest expense, net		53,378			35,653	
Provision for income taxes		52,499			57,401	
EBITDA net of NCI	\$	410,061	11.5%	\$	421,742	12.6%
Other (income) expense, net		11,472			6,015	
Adjusted EBITDA net of NCI	\$	421,533	11.8%	\$	427,757	12.8%
Net revenues	\$	3,562,774		\$	3,336,027	

Calculation of Adjusted Net Income Attributable to UHS

						Three months September 30		
				Per				Per
	10,528 0.15 10,528 0.15						Di	luted
		Amount	<u>S</u>	<u>Share</u>		Amount	Share	
Net income attributable to UHS	\$	166,989	\$	2.40	\$	182,814	\$	2.50
Plus/minus after-tax adjustments:								
Unrealized loss on equity securities		10,528		0.15		2,974		0.04
Subtotal adjustments		10,528		0.15		2,974		0.04
Adjusted net income attributable to UHS	\$	177,517	\$	2.55	\$	185,788	\$	2.54

Schedule of Non-GAAP Supplemental Information ("Supplemental Schedule").

For the Nine Months ended September 30, 2023 and 2022

(in thousands, except per share amounts)

(unaudited)

Calculation of Earnings/Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA/Adjusted EBITDA net of NCI")

	Nine	months ended	% Net	Nine	months ended	% Net
	<u>Septe</u>	ember <u>30, 2023</u>	<u>revenues</u>	<u>Septe</u>	<u>mber 30, 2022</u>	<u>revenues</u>
Net income attributable to UHS	\$	501,417		\$	500,789	
Depreciation and amortization		422,560			433,508	
Interest expense, net		153,085			83,002	
Provision for income taxes		159,618			157,312	
EBITDA net of NCI	\$	1,236,680	11.7 %	\$	1,174,611	11.8%
Other (income) expense, net		31,797			15,244	
Adjusted EBITDA net of NCI	\$	1,268,477	12.0 %	\$	1,189,855	12.0%
Net revenues	\$	10,578,430		\$	9,952,390	

Calculation of Adjusted Net Income Attributable to UHS

	Nine months September 30				Nine months September 30		
	Amount	Di	Per <u>luted</u> hare	Ĩ	Amount	Di	Per <u>luted</u> hare
Net income attributable to UHS	\$ 501,417	\$	7.09	\$	500,789	\$	6.71
Plus/minus after-tax adjustments:							
Unrealized loss on equity securities	23,040		0.33		12,358		0.17
Subtotal adjustments	 23,040		0.33		12,358		0.17
Adjusted net income attributable to UHS	\$ 524,457	\$	7.42	\$	513,147	\$	6.88

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)

	Sej	otember 30, 2023	December 31, 2022		
Assets					
Current assets:					
Cash and cash equivalents	\$	80,768	\$	102,818	
Accounts receivable, net		2,234,343		2,017,722	
Supplies		214,587		218,517	
Other current assets		223,303		198,283	
Total current assets		2,753,001		2,537,340	
Property and equipment		11,610,188		11,085,852	
Less: accumulated depreciation		(5,523,135)		(5,167,394)	
		6,087,053		5,918,458	
Other assets:					
Goodwill		3,912,122		3,909,456	
Deferred income taxes		99,580		68,397	
Right of use assets-operating leases		443,924		454,650	
Deferred charges		7,062		6,264	
Other		570,728		599,623	
Total Assets	\$	13,873,470	\$	13,494,188	
Liabilities and Stockholders' Equity					
Current liabilities:					
Current maturities of long-term debt	\$	126,555	\$	81,447	
Accounts payable and other liabilities		1,783,460		1,760,588	
Operating lease liabilities		72,655		67,776	
Federal and state taxes		7,145		4,608	
Total current liabilities		1,989,815		1,914,419	
Other noncurrent liabilities		587,829		487,669	
Operating lease liabilities noncurrent		388,550		395,522	
Long-term debt		4,796,074		4,726,533	
Redeemable noncontrolling interest		4,719		4,695	
UHS common stockholders' equity		6,064,915		5,920,582	
Noncontrolling interest		41,568		44,768	
Total equity		6,106,483		5,965,350	
Total Liabilities and Stockholders' Equity	\$	13,873,470	\$	13,494,188	

Consolidated Statements of Cash Flows

(in thousands) (unaudited)

(unaudited)				
		Nine n		
		ended Sept	embei	
		2023	. <u></u>	2022
Cash Flows from Operating Activities:	¢	100 005	¢	400.040
Net income	\$	499,685	\$	486,613
Adjustments to reconcile net income to net cash provided by operating activities:				100 500
Depreciation & amortization		422,560		433,508
(Gain) loss on sale of assets and businesses		(6,250)		584
Stock-based compensation expense		65,702		62,741
Changes in assets & liabilities, net of effects from acquisitions and dispositions:		(102,100)		(155 140)
Accounts receivable Accrued interest		(193,108)		(155,142
		60		529
Accrued and deferred income taxes		(33,240)		(4,900
Other working capital accounts		(65,062)		(173,903
Medicare accelerated payments and deferred CARES Act and other grants		1,764		2,921
Other assets and deferred charges		48,985		22,219
Other		13,717		(23,358
Accrued insurance expense, net of commercial premiums paid		141,414		134,908
Payments made in settlement of self-insurance claims		(80,861)		(88,001
Net cash provided by operating activities		815,366		698,719
Cash Flows from Investing Activities:				
Property and equipment additions		(536,665)		(569,555
Proceeds received from sales of assets and businesses		23,688		12,001
Acquisition of businesses and property		(3,728)		(18,666
(Outflows) inflows from foreign exchange contracts that hedge our net U.K. investment		(7,723)		177,214
Decrease in capital reserves of commercial insurance subsidiary		0		100
Net cash used in investing activities		(524,428)		(398,906
Cash Flows from Financing Activities:				
Repayments of long-term debt		(54,009)		(194,115
Additional borrowings		165,000		705,321
Financing costs		(308)		(2,541
Repurchase of common shares		(385,339)		(723,384
Dividends paid		(41,964)		(44,192
Issuance of common stock		9,841		10,399
Profit distributions to noncontrolling interests		(5,258)		(5,426
(Purchase) sale of ownership interests by (from) minority members		408		(49,089
Net cash used in financing activities		(311,629)		(303,027
Effect of exchange rate changes on cash, cash equivalents and restricted cash		493		(10,339
Decrease in cash, cash equivalents and restricted cash		(20,198)		(13,553
Cash, cash equivalents and restricted cash, beginning of period		200,837		178,934
Cash, cash equivalents and restricted cash, end of period	\$	180,639	\$	165,381
Supplemental Disclosures of Cash Flow Information:				
Interest paid	\$	149,247	\$	78,992
Income taxes paid, net of refunds	\$	191,189	\$	182,091
Noncash purchases of property and equipment	\$	108,412	\$	97,264

Supplemental Statistical Information

	% Change	% Change
Same Facility:	Three Months ended	Nine Months ended
	9/30/2023	9/30/2023
Acute Care Services		
Revenues	7.5%	6.9%
Adjusted Admissions	6.8%	8.3%
Adjusted Patient Days	3.8%	4.8%
Revenue Per Adjusted Admission	0.4%	-2.0%
Revenue Per Adjusted Patient Day	3.3%	1.3%
Behavioral Health Care Services		
Revenues	7.6%	8.3%
Adjusted Admissions	0.8%	3.8%
Adjusted Patient Days	1.1%	2.4%
Revenue Per Adjusted Admission	6.8%	4.4%
Revenue Per Adjusted Patient Day	6.5%	5.9%

UHS Consolidated	Third quart	er ended	Nine months ended		
	9/30/2023	9/30/2022	9/30/2023	9/30/2022	
Revenues	\$3,562,774	\$3,336,027	\$10,578,430	\$9,952,390	
EBITDA net of NCI	\$410,061	\$421,742	\$1,236,680	\$1,174,611	
EBITDA Margin net of NCI	11.5%	12.6%	11.7%	11.8%	
Adjusted EBITDA net of NCI	\$421,533	\$427,757	\$1,268,477	\$1,189,855	
Adjusted EBITDA Margin net of NCI	11.8%	12.8%	12.0%	12.0%	
Cash Flow From Operations	\$161,665	\$220,672	\$815,366	\$698,719	
Capital Expenditures	\$200,001	\$161,593	\$536,665	\$569,555	
Days Sales Outstanding			58	52	
Debt			\$4,922,629	\$4,704,663	
UHS' Shareholders Equity			\$6,064,915	\$5,855,353	
Debt / Total Capitalization			44.8%	44.6%	
Debt / EBITDA net of NCI (1)			2.97	2.87	
Debt / Adjusted EBITDA net of NCI (1)			2.83	2.87	
Debt / Cash From Operations (1)			4.42	4.61	
(1) Latest A quarters					

(1) Latest 4 quarters.

Acute Care Hospital Services For the Three and Nine Months ended September 30, 2023 and 2022 (in thousands)

Same Facility Basis - Acute Care Hospital Services

		Three months ended September 30, 2023		ths ended 30, 2022	Nine mont September				
	Amount	% of Net Revenu es	Amount	% of Net Revenues	Amount	% of Net Revenues	Amount	% of Net Revenues	
Net revenues	\$ 1,965,856	100.0 %	\$ 1,828,370	100.0 %	\$ 5,808,205	100.0 %	\$ 5,432,868	100.0 %	
Operating charges:									
Salaries, wages and benefits	854,215	43.5 %	801,252	43.8%	2,493,271	42.9%	2,412,699	44.4%	
Other operating expenses	543,707	27.7%	478,221	26.2%	1,584,820	27.3%	1,382,250	25.4%	
Supplies expense	324,226	16.5 %	302,162	16.5%	964,228	16.6%	904,547	16.6%	
Depreciation and amortization	86,583	4.4%	92,830	5.1%	265,021	4.6%	274,574	5.1%	
Lease and rental expense	24,404	1.2 %	21,847	1.2%	71,635	1.2 %	62,756	1.2%	
Subtotal-operating expenses	1,833,135	93.2 %	1,696,312	92.8%	5,378,975	92.6%	5,036,826	92.7 %	
Income from operations	132,721	6.8%	132,058	7.2%	429,230	7.4%	396,042	7.3%	
Interest expense, net	(778)	(0.0)%	234	0.0%	(1,858)	(0.0)%	5 1,350	0.0%	
Other (income) expense, net	(1,045)	(0.1)%	384	0.0%	5,168	0.1%	806	0.0%	
Income before income taxes	\$ 134,544	6.8%	\$ 131,440	7.2%	\$ 425,920	7.3%	\$ 393,886	7.3%	

All Acute Care Hospital Services

		Three months ended September 30, 2023		ths ended 30, 2022	Nine mont September		Nine mont September	
	Amount	% of Net Revenu es	Amount	% of Net Revenues	Amount	% of Net Revenues	Amount	% of Net Revenues
Net revenues	\$ 2,017,288	100.0 %	\$ 1,919,678	100.0 %	\$ 5,993,899	100.0 %	\$ 5,707,510	100.0 %
Operating charges:								
Salaries, wages and benefits	854,587	42.4%	824,942	43.0%	2,534,878	42.3%	2,497,888	43.8%
Other operating expenses	596,834	29.6%	535,463	27.9%	1,731,750	28.9%	1,550,044	27.2%
Supplies expense	323,475	16.0%	311,404	16.2%	979,185	16.3%	935,559	16.4%
Depreciation and amortization	86,535	4.3%	96,020	5.0%	274,165	4.6 %	285,558	5.0%
Lease and rental expense	24,440	1.2 %	21,990	1.1 %	72,629	1.2 %	63,324	1.1%
Subtotal-operating expenses	1,885,871	93.5 %	1,789,819	93.2 %	5,592,607	93.3 %	5,332,373	93.4%
Income from operations	131,417	6.5 %	129,859	6.8%	401,292	6.7%	375,137	6.6%
Interest expense, net	(778)	(0.0)%	234	0.0%	(1,858)	(0.0)%	1,350	0.0%
Other (income) expense, net	(211)	(0.0)%	384	0.0%	6,921	0.1 %	806	0.0%
Income before income taxes	\$ 132,406	6.6%	\$ 129,241	6.7%	\$ 396,229	6.6%	\$ 372,981	6.5%

We believe that providing our results on a "Same Facility" basis (which is a non-GAAP measure), which includes the operating results for facilities and businesses operated in both the current year and prior year periods, is helpful to our investors as a measure of our operating performance. Our Same Facility results also neutralize (if applicable), the effect of material items that are nonrecurring or non-operational in nature including items such as, but not limited to, reserves for various matters, settlements, legal judgments and lawsuits, cost related to extinguishment of debt, gains/losses on sales of assets and businesses, impairments of goodwill, long-lived and intangible assets and other amounts that may be reflected in the current or prior year financial statements that relate to prior periods. Our Same Facility basis results exclude from net revenues and other operating expenses, provider tax assessments incurred in each period. However, these provider tax assessments are included in net revenues and other operating expenses as reflected in the table under All Acute Care Hospital Services. The provider tax assessments had no impact on the income before income taxes as reflected on the above tables since the amounts offset between net revenues and other operating expenses. To obtain a complete understanding of our financial performance, the Same Facility results should be examined in connection with our net income as determined in accordance with GAAP and as presented herein and the condensed consolidated financial statements and notes thereto as contained in our Form 10-K for the year ended December 31, 2022 and Form 10-Q for the quarter ended June 30, 2023.

The All Acute Care Hospital Services table summarizes the results of operations for all our acute care operations during the periods presented. These amounts include: (i) our acute care results on a same facility basis, as indicated above; (ii) the impact of provider tax assessments which increased net revenues and other operating expenses but had no impact on income before income taxes, and; (iii) certain other amounts including the results of facilities acquired or opened during the last twelve months.

Behavioral Health Care Services For the Three and Nine Months ended September 30, 2023 and 2022 (in thousands)

Same Facility - Behavioral Health Care Services

		Three months ended September 30, 2023		ths ended 30, 2022	Nine mont September		Nine months ended September 30, 2022	
	Amount	% of Net Revenu es	Amount	% of Net Revenues	Amount	% of Net Revenues	Amount	% of Net Revenues
Net revenues	\$ 1,513,354	100.0 %	\$ 1,407,039	100.0 %	\$ 4,490,078	100.0 %	\$ 4,144,998	100.0 %
Operating charges:								
Salaries, wages and benefits	841,985	55.6%	779,839	55.4%	2,491,153	55.5%	2,293,332	55.3%
Other operating expenses	292,878	19.4%	273,618	19.4%	866,450	19.3%	816,312	19.7 %
Supplies expense	55,102	3.6%	55,466	3.9%	161,205	3.6%	157,457	3.8%
Depreciation and amortization	47,484	3.1 %	46,487	3.3%	139,039	3.1%	137,249	3.3%
Lease and rental expense	10,857	0.7 %	10,586	0.8%	32,642	0.7%	31,262	0.8%
Subtotal-operating expenses	1,248,306	82.5 %	1,165,996	82.9%	3,690,489	82.2 %	3,435,612	82.9%
Income from operations	265,048	17.5 %	241,043	17.1 %	799,589	17.8%	709,386	17.1 %
Interest expense, net	1,255	0.1%	1,370	0.1%	3,326	0.1%	3,957	0.1%
Other (income) expense, net	(985)	(0.1)%	(664)	(0.0)%	(2,294)	(0.1)%	(1,422)	(0.0)%
Income before income taxes	\$ 264,778	17.5%	\$ 240,337	17.1%	\$ 798,557	17.8%	\$ 706,851	17.1%

All Behavioral Health Care Services

	Three month September 3		Three mont September		Nine mont September		Nine mont September	
	Amount	% of Net Revenu es	Amount	% of Net Revenues	Amount	% of Net Revenues	Amount	% of Net Revenues
Net revenues	\$ 1,542,695	100.0 %	\$ 1,434,828	100.0 %	\$ 4,575,378	100.0 %	\$ 4,235,215	100.0 %
Operating charges:								
Salaries, wages and benefits	844,244	54.7 %	782,909	54.6%	2,498,338	54.6%	2,310,761	54.6%
Other operating expenses	322,208	20.9 %	300,406	20.9%	949,958	20.8%	898,655	21.2%
Supplies expense	55,272	3.6 %	55,482	3.9%	161,597	3.5%	158,315	3.7 %
Depreciation and amortization	47,720	3.1 %	46,861	3.3%	140,117	3.1%	138,803	3.3%
Lease and rental expense	10,911	0.7 %	11,010	0.8%	32,834	0.7%	32,803	0.8%
Subtotal-operating expenses	1,280,355	83.0 %	1,196,668	83.4%	3,782,844	82.7 %	3,539,337	83.6%
Income from operations	262,340	17.0 %	238,160	16.6%	792,534	17.3%	695,878	16.4%
Interest expense, net	1,252	0.1%	1,375	0.1%	3,456	0.1%	4,106	0.1%
Other (income) expense, net	(1,080)	(0.1)%	(1,164)	(0.1)%	(3,139)	(0.1)%	(1,922)	(0.0)%
Income before income taxes	\$ 262,168	17.0 %	\$ 237,949	16.6%	\$ 792,217	17.3%	\$ 693,694	16.4%

We believe that providing our results on a "Same Facility" basis (which is a non-GAAP measure), which includes the operating results for facilities and businesses operated in both the current year and prior year periods, is helpful to our investors as a measure of our operating performance. Our Same Facility results also neutralize (if applicable), the effect of material items that are nonrecurring or non-operational in nature including items such as, but not limited to, reserves for various matters, settlements, legal judgments, lawsuits and reserves established in connection with the government's investigation of our behavioral health care facilities, cost related to extinguishment of debt, gains/losses on sales of assets and businesses, impairments of goodwill, long-lived and intangible assets and other amounts that may be reflected in the current or prior year financial statements that relate to prior periods. Our Same Facility basis results exclude from net revenues and other operating expenses, provider tax assessments incurred in each period. However, these provider tax assessments had no impact on the income before income taxes as reflected on the above tables since the amounts offset between net revenues and other operating performance, the Same Facility results should be examined in connection with our net income as determined in accordance with GAAP and as presented herein and in the condensed consolidated financial statements and notes thereto as contained in our Form 10-K for the year ended December 31, 2022 and Form 10-Q for the quarter ended June 30, 2023.

The All Behavioral Health Care Services table summarizes the results of operations for all our behavioral health care facilities during the periods presented. These amounts include: (i) our behavioral health results on a same facility basis, as indicated above; (ii) the impact of provider tax assessments which increased net revenues and other operating expenses but had no impact on income before income taxes, and; (iii) certain other amounts including the results of facilities acquired or opened during the last twelve months as well as the results of certain facilities that were closed or restructured during the past year.

Selected Hospital Statistics For the Three Months Ended September 30, 2023 and 2022

AS REPORTED:

AS KEI OKIED.						
		ACUTE		BEH	AVIORAL HEAD	LTH
	09/30/23	09/30/22	% change	09/30/23	09/30/22	% change
Hospitals owned and leased	27	28	-3.6%	331	331	0.0%
Average licensed beds	6,667	6,982	-4.5%	24,194	24,222	-0.1 %
Average available beds	6,495	6,810	-4.6%	24,094	24,122	-0.1 %
Patient days	384,348	386,341	-0.5 %	1,600,740	1,588,532	0.8%
Average daily census	4,177.7	4,199.4	-0.5%	17,399.3	17,266.7	0.8%
Occupancy-licensed beds	62.7%	60.1%	4.2%	71.9%	71.3%	0.9%
Occupancy-available beds	64.3%	61.7%	4.3%	72.2%	71.6%	0.9%
Admissions	80,074	78,221	2.4%	118,487	117,913	0.5%
Length of stay	4.8	4.9	-2.8%	13.5	13.4	0.8%
Inpatient revenue	\$ 10,916,060	\$ 9,875,794	10.5%	\$ 2,703,478	\$ 2,582,448	4.7%
Outpatient revenue	7,480,353	6,379,324	17.3%	259,060	248,167	4.4%
Total patient revenue	 18,396,413	16,255,118	13.2 %	2,962,538	2,830,615	4.7%
Other revenue	251,985	215,179	17.1%	81,149	67,228	20.7 %
Gross hospital revenue	18,648,398	16,470,297	13.2 %	3,043,687	2,897,843	5.0%
Total deductions	16,631,110	14,550,619	14.3%	1,500,992	1,463,015	2.6%
Net hospital revenue	\$ 2,017,288	\$ 1,919,678	5.1%	\$ 1,542,695	\$ 1,434,828	7.5%
•						

SAME FACILITY:

		ACUTE	BEHA	WIORAL HEA	LTH	
	09/30/23	09/30/22	% change	09/30/23	09/30/22	% change
Hospitals owned and loaced	27	27	0.0%	329	329	0.0 %
Hospitals owned and leased						
Average licensed beds	6,667	6,700	-0.5%	23,983	24,077	-0.4 %
Average available beds	6,495	6,528	-0.5 %	23,883	23,977	-0.4 %
Patient days	384,348	372,480	3.2 %	1,589,806	1,577,358	0.8%
Average daily census	4,177.7	4,048.7	3.2%	17,280.5	17,145.2	0.8%
Occupancy-licensed beds	62.7%	60.4%	3.7%	72.1%	71.2%	1.2 %
Occupancy-available beds	64.3%	62.0%	3.7%	72.4%	71.5%	1.2 %
Admissions	80,074	75,434	6.2%	117,620	117,008	0.5%
Length of stay	4.8	4.9	-2.8%	13.5	13.5	0.3%

Selected Hospital Statistics For the Nine Months Ended September 30, 2023 and 2022

AS REPORTED:

AS REPORTED:								
			ACUTE		BEH	IAVI	ORAL HEALTH	
		09/30/23	09/30/22	% change	 09/30/23		09/30/22	% change
Hospitals owned and leased		27	28	-3.6%	331		331	0.0%
Average licensed beds		6,697	6,901	-3.0%	24,203		24,269	-0.3%
Average available beds		6,525	6,729	-3.0%	24,103		24,169	-0.3%
Patient days		1,172,957	1,168,248	0.4%	4,761,887		4,669,598	2.0%
Average daily census		4,296.5	4,279.3	0.4%	17,442.8		17,104.8	2.0%
Occupancy-licensed beds		64.2 %	62.0%	3.5%	72.1%		70.5%	2.3%
Occupancy-available beds		65.8%	63.6%	3.5%	72.4%		70.8%	2.3%
Admissions		239,300	230,223	3.9%	358,703		346,973	3.4%
Length of stay		4.9	5.1	-3.4%	13.3		13.5	-1.4%
Inpatient revenue	\$	33,278,396	\$ 29,821,756	11.6%	\$ 8,001,838	\$	7,580,475	5.6%
Outpatient revenue		22,292,249	18,360,902	21.4%	812,467		773,769	5.0%
Total patient revenue		55,570,645	48,182,658	15.3%	 8,814,305		8,354,244	5.5%
Other revenue		714,877	602,635	18.6%	220,393		209,284	5.3%
Gross hospital revenue		56,285,522	 48,785,293	15.4%	9,034,698		8,563,528	5.5%
Total deductions		50,291,623	43,077,783	16.7%	4,459,320		4,328,313	3.0%
Net hospital revenue	\$	5,993,899	\$ 5,707,510	5.0%	\$ 4,575,378	\$	4,235,215	8.0 %
	-							

SAME FACILITY:

		ACUTE		BEHA	VIORAL HEALTH	
	09/30/23	09/30/22	% change	09/30/23	09/30/22	% change
Hospitals owned and leased	27	27	0.0%	329	329	0.0%
Average licensed beds	6,581	6,619	-0.6%	24,010	23,985	0.1%
Average available beds	6,409	6,447	-0.6%	23,910	23,885	0.1 %
Patient days	1,161,260	1,124,897	3.2%	4,726,012	4,625,248	2.2%
Average daily census	4,253.7	4,120.5	3.2%	17,311.4	16,942.3	2.2 %
Occupancy-licensed beds	64.6%	62.3%	3.8%	72.1%	70.6%	2.1%
Occupancy-available beds	66.4%	63.9%	3.8%	72.4%	70.9%	2.1%
Admissions	236,911	221,868	6.8%	355,419	343,014	3.6%
Length of stay	4.9	5.1	-3.3%	13.3	13.5	-1.4%